In the wake of Biocon’s debut positive opinion for an aflibercept rival to Eylea just over a year ago, two further companies – Sandoz and Samsung Bioepis – have now secured coveted endorsements from the European Medicines Agency for their own versions of the ophthalmic biosimilar. Meanwhile, Teva has received a CHMP nod for another Imnovid generic.

Samsung Bioepis and Alexion have brought patent proceedings over Soliris to an end in the US, clearing the way for the Korean firm to launch its Epysqli biosimilar version of eculizumab. However, Amgen is also waiting in the wings with its own rival.

Days after Sandoz received US FDA approval for its Enzeevu aflibercept biosimilar, Regeneron sued alleging that Sandoz failed to follow the “patent dance” set out in the BPCIA framework and claiming infringement of multiple patents on its Eylea.

Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.